Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:CRIS NASDAQ:DOMH NASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$4.05$4.61$3.75▼$7.20$7.78M1.1631,757 shs4,406 shsCRISCuris$0.35$0.48$0.18▼$2.01$13.51M3.089.07 million shs2.36 million shsDOMHDominari$2.94$3.22$2.68▼$8.40$66.49M0.84148,259 shs134,854 shsSGMOSangamo Therapeutics$0.07$0.15$0.06▼$0.77$30.66M1.38.10 million shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%-5.37%-14.92%-5.59%-31.47%CRISCuris0.00%+14.01%-30.68%-36.97%-80.19%DOMHDominari0.00%+0.34%-9.82%+6.91%-44.00%SGMOSangamo Therapeutics0.00%0.00%-64.86%-75.34%-86.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$4.05$4.61$3.75▼$7.20$7.78M1.1631,757 shs4,406 shsCRISCuris$0.35$0.48$0.18▼$2.01$13.51M3.089.07 million shs2.36 million shsDOMHDominari$2.94$3.22$2.68▼$8.40$66.49M0.84148,259 shs134,854 shsSGMOSangamo Therapeutics$0.07$0.15$0.06▼$0.77$30.66M1.38.10 million shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%-5.37%-14.92%-5.59%-31.47%CRISCuris0.00%+14.01%-30.68%-36.97%-80.19%DOMHDominari0.00%+0.34%-9.82%+6.91%-44.00%SGMOSangamo Therapeutics0.00%0.00%-64.86%-75.34%-86.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.40Hold$34.67755.97% UpsideCRISCuris 1.67Reduce$17.004,804.79% UpsideDOMHDominari 1.00SellN/AN/ASGMOSangamo Therapeutics 1.75Reduce$5.507,332.43% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, DOMH, SGMO, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026BOLTBolt Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/28/2026BOLTBolt Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/22/2026CRISCuris Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/20/2026BOLTBolt Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRISCuris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026SGMOSangamo Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.70M1.01N/AN/A$13.81 per share0.29CRISCuris$9.44M1.43N/AN/A$0.42 per share0.83DOMHDominari$123.10M0.54N/AN/A$4.28 per share0.69SGMOSangamo Therapeutics$39.55M0.78N/AN/A($0.04) per share-1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$33.38M-$16.33N/AN/AN/A-455.15%-100.89%-48.23%8/13/2026 (Estimated)CRISCuris-$7.58M-$1.19N/AN/AN/A-80.29%N/A-181.57%8/4/2026 (Estimated)DOMHDominari-$22.43M-$4.03N/AN/AN/A-31.37%-206.20%-155.26%8/18/2026 (Estimated)SGMOSangamo Therapeutics-$122.93M-$0.38N/AN/AN/A-310.81%-2,662.06%-132.12%8/6/2026 (Estimated)Latest CRIS, DOMH, SGMO, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DOMHDominari-$0.17-$2.11-$1.94-$3.17$35.81 million$35.81 million5/12/2026Q1 2026BOLTBolt Biotherapeutics-$2.85-$4.31-$1.46-$4.31$1.50 million$0.03 million5/12/2026Q1 2026CRISCuris-$0.3267-$1.25-$0.9233-$1.25$1.69 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ALatest CRIS, DOMH, SGMO, and BOLT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/4/2026DOMHDominarispecial$0.315/15/20265/15/20265/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.983.513.51CRISCurisN/A1.111.11DOMHDominariN/A1.411.41SGMOSangamo TherapeuticsN/A0.840.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CRISCuris29.97%DOMHDominari42.48%SGMOSangamo Therapeutics56.92%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics9.40%CRISCuris5.78%DOMHDominari55.30%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.74 millionNot OptionableCRISCuris6038.98 million36.73 millionNo DataDOMHDominari422.61 million10.11 millionNot OptionableSGMOSangamo Therapeutics480414.29 million397.29 millionOptionableCRIS, DOMH, SGMO, and BOLT HeadlinesRecent News About These CompaniesSangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and AstellasJune 24, 2026 | markets.businessinsider.comSangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assetsJune 24, 2026 | seekingalpha.comSangamo Therapeutics files for Chapter 11 bankruptcyJune 24, 2026 | msn.comSangamo Therapeutics Initiates Chapter 11 and Asset SalesJune 23, 2026 | tipranks.comSangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for StakeholdersJune 8, 2026 | globenewswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comSangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...May 16, 2026 | finance.yahoo.comSangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the PeriodMay 16, 2026 | tipranks.comSangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2026 | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comSangamo Therapeutics Announces First Quarter 2026 Earnings CallMay 11, 2026 | markets.businessinsider.comSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketMay 5, 2026 | finanznachrichten.deSangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)April 30, 2026 | globenewswire.comSangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB marketApril 29, 2026 | finance.yahoo.comSangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketApril 29, 2026 | globenewswire.comSangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in StockApril 24, 2026 | insidertrades.comSangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth UncertaintyApril 1, 2026 | tipranks.comSangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsMarch 31, 2026 | finanznachrichten.deWhy PEPG, SGMO, PHR are among top premarket losers todayMarch 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 20265 Stocks Solving the AI Power CrisisBy Ryan Hasson | June 22, 2026CRIS, DOMH, SGMO, and BOLT Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$4.05 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.86 -0.19 (-4.67%) As of 07/2/2026 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Curis NASDAQ:CRIS$0.35 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.36 +0.01 (+3.58%) As of 07/2/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Dominari NASDAQ:DOMH$2.94 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.03 +0.09 (+3.13%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Sangamo Therapeutics NASDAQ:SGMO$0.07 0.00 (0.00%) As of 07/2/2026Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
